ATRA Stock Posts

ATRA Atara Biotherapeutics9.81+1.03+11.7%

After Hours:9.24-0.57 (-5.8%)

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Business WireTue, 12-May 4:05 PM

ATRA Atara Biotherapeutics9.81+1.03+11.7%

After Hours:9.24-0.57 (-5.8%)

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Business WireTue, 12-May 4:05 PM

ATRA Atara Biotherapeutics8.78+0.44+5.3%

After Hours:9.11+0.33 (+3.8%)

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Globe NewswireMon, 11-May 7:53 PM

ATRA Atara Biotherapeutics8.34-1.59-16.0%

After Hours:9.40+1.06 (+12.7%)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NewsfileFri, 8-May 6:26 PM

ATRA Atara Biotherapeutics8.34-1.59-16.0%

After Hours:8.84+0.50 (+6.0%)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NewsfileFri, 8-May 6:26 PM

ATRA Atara Biotherapeutics13.67-3.77-21.6%

Premarket:6.74-6.93 (-50.7%)

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

PRNewswireMon, 12-Jan 8:05 AM